$0.89
1.23% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US16934W1062
Symbol
CMRX
Sector
Industry

Chimerix, Inc. Stock price

$0.89
-0.09 9.18% 1M
-0.12 11.64% 6M
-0.07 7.28% YTD
-0.12 11.64% 1Y
-5.92 86.90% 3Y
-1.61 64.30% 5Y
-27.97 96.91% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.01 1.23%
ISIN
US16934W1062
Symbol
CMRX
Sector
Industry

Key metrics

Market capitalization $80.99m
Enterprise Value $-65.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.97
EV/Sales (TTM) EV/Sales -469.07
P/S ratio (TTM) P/S ratio 578.50
P/B ratio (TTM) P/B ratio 0.52
Revenue growth (TTM) Revenue growth -99.57%
Revenue (TTM) Revenue $140.00k
EBIT (operating result TTM) EBIT $-94.72m
Free Cash Flow (TTM) Free Cash Flow $-68.02m
Cash position $148.17m
EPS (TTM) EPS $-0.95
P/E forward negative
P/S forward 8.13
EV/Sales forward negative
Short interest 2.36%
Show more

Is Chimerix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Chimerix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Chimerix, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Chimerix, Inc. forecast:

Buy
100%

Financial data from Chimerix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.14 0.14
100% 100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
18% 18%
17,521%
- Research and Development Expense 70 70
0% 0%
50,221%
-95 -95
64% 64%
-67,664%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -95 -95
64% 64%
-67,658%
Net Profit -85 -85
147% 147%
-60,500%

In millions USD.

Don't miss a Thing! We will send you all news about Chimerix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Chimerix, Inc. Stock News

Neutral
GlobeNewsWire
28 days ago
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the aw...
Neutral
Seeking Alpha
about 2 months ago
Chimerix, Inc. (NASDAQ:CMRX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Officer Michelle LaSpaluto - Chief Financial Officer Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Part...
Neutral
GlobeNewsWire
3 months ago
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awar...
More Chimerix, Inc. News

Company Profile

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Head office United States
CEO Michael Andriole
Employees 72
Founded 2000
Website www.chimerix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today